Global 3D Cell Culture Market Research Report 2022: More than 140 Companies Offer 3D Cell Culture Systems in a Variety of Formats

08 Jun 2022
www.prnewswire.com
Collaborate
DUBLIN, June 8, 2022 /PRNewswire/ -- The "3D Cell Culture Market by Scaffold Format, Products, Application Areas, Purpose, and Key Geographical Regions: Industry Trends and Global Forecasts, 2022-2035" report has been added to
ResearchAndMarkets.com's offering.
The "3D Cell Culture Market" report features an extensive study of the current landscape, offering an informed opinion on the likely evolution of the market in the mid to long term. The study also features an in-depth analysis, highlighting the capabilities of various industry stakeholders engaged in this domain.
At present, more than 140 companies offer 3D cell culture systems in a variety of formats, including scaffold-based products, scaffold-free products and 3D bioreactors.
These systems have demonstrated to be capable of more accurately simulating the natural tissue microenvironment, offer increased cell-to-cell and cell-to-ECM interactions, more accurate evaluation of drug toxicity and cellular responses, and co-cultuirng of multiple cell types together.
Moreover, there are certain complex 3D cell culture models that can even replace animal models exhibiting reproducible results and thereby, serving as better in vivo models across multiple application areas. Given the various benefits of such systems, the field has garnered the attention of various venture capital firms and strategic investors that have been providing financial support to drive research efforts focused on exploring different formats of 3D cell culture systems, including organoids and organ-on-chips across multiple application areas.
Moreover, there has been an increase in scientific literature on 3D cell culture systems and collaborations for 3D bioreactors and cell culture products. Given the ongoing innovation in this field, and the paradigm shift from 2D cell culture systems and animal testing to 3D cell culture models, the market is likely to witness a significant growth in the foreseen future.
The report features detailed transcripts of interviews held with the following industry and non-industry players:
Brigitte Angres (Co-founder, Cellendes)
Bill Anderson (President and CEO, Synthecon)
Anonymous (President and CEO, Anonymous)
Anonymous (Co-founder and Vice President, Anonymous)
Scott Brush (Vice President, BRTI Life Sciences)
Malcolm Wilkinson (Managing Director, Kirkstall)
Ryder Clifford (Director, QGel) and Simone Carlo Rizzi (Chief Scientific Officer, QGel)
Tanya Yankelevich (Director, Xylyx Bio)
Jens Kelm (Chief Scientific Officer, InSphero)
Walter Tinganelli (Group Leader, GSI)
Darlene Thieken (Project Manager, Nanofiber Solutions)
Andrea Picon (Director, Business Development, FlexCell International)
Frank Junker (Chief Business Officer, InSphero)
Mohammed Mamunur Rahman (Manager, Business Development, MBL International)
Key Questions Answered
Who are the leading industry players engaged in the development of 3D cell culture products?
Which are the most popular 3D cell culture products?
Which are the different application areas for which 3D cell culture products are being developed?
What are the key factors that are likely to influence the evolution of 3D cell culture systems market?
What is the trend of capital investments in the 3D cell culture systems market?
Which partnership models are commonly adopted by stakeholders in 3D cell culture market?
How is the current and future opportunity likely to be distributed across key market segments?
What are the anticipated future trends related to 3D cell culture systems market?
Key Topics Covered:
1. PREFACE
3. INTRODUCTION
3.1. Chapter Overview
3.2. Types of Cell Cultures
3.3. Morphology of Cells in Culture
3.4. 2D Cell Cultures vs 3D Cell Cultures
3.5. Overview of 3D Cell Culturing
3.6. Establishment and Maintenance of Cell Cultures
3.7. Requirements for Maintaining Healthy Cell Cultures
3.8. Applications of 3D Cell Culture Systems
3.9. Advantages and Limitations of 3D Cell Culture Systems
3.10. Future Perspectives
4. CLASSIFICATION OF 3D CELL CULTURE SYSTEMS
4.1. 3D Cell Culture Classification
4.2. Scaffold Based 3D Cell Cultures
4.3. Scaffold Free 3D Cell Cultures
4.4. Organoids
5. FABRICATION OF 3D MATRICES AND SCAFFOLDS
5.1. Chapter Overview
5.2. Methods for Fabricating Porous Scaffolds
5.3. Methods for Fabricating Fibrous Scaffolds
5.4. Methods for Fabricating Hydrogels
5.5. Methods for Fabricating Custom Scaffolds
5.6. Methods for Fabricating Microspheres
5.7. Methods for Fabricating Native Scaffolds
6.1. Chapter Overview
6.2. 3D Cell Culture System Developers: Overall Market Landscape
6.3. 3D Cell Cultures: List of Service Providers
6.4. 3D Cell Cultures: List of Affiliated Assays, Kits and Reagents
7. MARKET LANDSCAPE: SCAFFOLD BASED PRODUCTS
7.1. Chapter Overview
7.2. Scaffold Based Products: Overall Market Landscape
7.3. Scaffold Based Products: Developer Landscape
8. MARKET LANDSCAPE: SCAFFOLD FREE PRODUCTS
8.1. Chapter Overview
8.2. Scaffold Free Products: Overall Market Landscape
8.3. Scaffold Free Products: Developer Landscape
9. MARKET LANDSCAPE: 3D BIOREACTORS
9.1. Chapter Overview
9.2. 3D Bioreactors: Overall Market Landscape
9.3. 3D Bioreactors: Developer Landscape
10. KEY APPLICATION AREAS
10.1. Chapter Overview
10.2. 3D Cell Culture Systems in Cancer Research
10.3. 3D Cell Culture Systems in Drug Discovery and Toxicity Screening
10.4. 3D Cell Culture Systems in Stem Cell Research
10.5. 3D Cell Cultures in Regenerative Medicine and Tissue Engineering
10.6. 3D Cell Culture Systems: Analysis by Key Application Areas
11. COMPANY PROFILES: SCAFFOLD BASED PRODUCTS (HYDROGEL / ECM DEVELOPERS)
11.1. Chapter Overview
11.1.1. 3D Biotek
11.1.3. Alphabioregen
11.1.5. REPROCELL
12. COMPANY PROFILES: SCAFFOLD FREE PRODUCTS (ORGAN-ON-CHIPS DEVELOPERS)
12.1. Chapter Overview
12.1.2. Emulate
12.1.3. InSphero
12.1.4. MIMETAS
12.1.5. TissUse
13. COMPANY PROFILES: 3D BIOREACTORS
13.1. Chapter Overview
13.2. BISS TGT
13.3. Celartia
13.5. EBERS
13.8. Synthecon
14. FUNDING AND INVESTMENT ANALYSIS
14.1. Chapter Overview
14.2. Types of Funding
14.3. 3D Cell Culture Systems: Funding and Investment Analysis
14.4 Summary of Funding and Investments
15. PARTNERSHIPS AND COLLABORATIONS
15.1. Chapter Overview
15.2. Partnership Models
15.3. 3D Cell Culture Systems: List of Partnerships and Collaborations
16. PATENT ANALYSIS
16.1. Chapter Overview
16.2. Scope and Methodology
16.3. 3D Cell Culture Systems: Patent Analysis
16.4. 3D Cell Culture Systems: Patent Valuation Analysis
16.5. Leading Patents: Analysis by Number of Citations
17. PUBLICATION ANALYSIS
17.1. 3D Cell Culture Systems: Publication Analysis
17.2. Assumptions and Key Parameters
17.3. Methodology
18. PRODUCT COMPETITIVENESS ANALYSIS
18.1. Chapter Overview
18.2. Assumptions / Key Parameters
18.3. Methodology
18.4. Product Competitiveness Analysis: 3D Bioreactors
19. CASE STUDY: ORGANIDS AND ORGAN-ON-CHIPS
19.1. Chapter Overview
19.2. Organoids and Organ-on-Chips: List of Products
19.3. Organoids and Organ-on-Chips: List of Product Developers
20. MARKET FORECAST
20.1. Chapter Overview
20.2. Key Assumptions and Forecast Methodology
20.3. Global 3D Cell Culture Market, 2022-2035
20.4. Global 3D Cell Culture Market: Distribution by Business Segment
20.5. Global 3D Cell Culture Systems Market: Distribution by 3D Cell Culture Format
20.6. Global 3D Cell Culture Systems Market: Distribution by Type of Product
20.7. Global 3D Cell Culture Systems Market: Distribution by Area of Application
20.8. Global 3D Cell Culture Systems Market: Distribution by Purpose
20.9. Global 3D Cell Culture Systems Market: Distribution by Geography
21.1. Chapter Overview
21.2. Overview of Respondents
21.2.1. Designation of Respondents
21.3. Survey Insights
21.3.1. 3D Cell Culture Format
21.3.2. Type of Product(s) Offered
21.3.3. Status of Development of Product(s)
21.3.4. Source of 3D Cultured Cells
21.3.5. Method Used for Fabrication
21.3.6. Area(s) of Application
21.3.7. Services Offered for 3D Cell Cultures
21.3.8. Current and Future Market Opportunity
22. CONCLUSION
23. EXECUTIVE INSIGHTS
23.1. Chapter Overview
23.2. Cellendes
23.2.1. Company Snapshot
23.2.2. Interview Transcript: Brigitte Angres, Co-founder
23.3. Synthecon
23.3.1. Company Snapshot
23.3.2. Interview Transcript: Bill Anderson, President and Chief Executive Officer
23.4. Anonymous
23.4.1. Interview Transcript: Anonymous, President and Chief Executive Officer
23.5. Anonymous
23.5.1. Interview Transcript: Anonymous, Co-founder and Vice President
23.6.1. Company Snapshot
22.6.2. Interview Transcript: Scott Brush, Vice President
23.7. Kirkstall
23.7.1. Company Snapshot
23.7.2. Interview Transcript: Malcolm Wilkinson, Non-Executive Director
23.8. QGel
23.8.1. Company Snapshot
23.8.2. Interview Transcript: Ryder Clifford, Chief Executive Officer and Simone Carlo Rizzi, Chief Scientific Officer
23.9. Xylyx Bio
23.9.1. Company Snapshot
23.9.2. Interview Transcript: Tanya Yankelevich, Former Director of Product Management and Business Development
23.10. InSphero
23.10.1. Company Snapshot
23.10.2. Interview Transcript: Jens Kelm, Former Chief Scientific Officer
23.11. GSI
23.11.1. Company Snapshot
23.11.2. Interview Transcript: Walter Tinganelli, Group Leader, Clinical Radiobiology
23.12.1. Company Snapshot
23.12.2. Interview Transcript: Darlene Thieken, Former Project Manager
23.13.1. Company Snapshot
23.13.2. Interview Transcript: Andrea Picon, Director of Business Development
23.14. InSphero
23.14.1. Company Snapshot
23.14.2. Interview Transcript: Frank Junker, Chief Business officer
23.15.1. Company Snapshot
23.15.2. Interview Transcript: Mamun, Rahman, Manger, Business Development
24. APPENDIX I: TABULATED DATA
25. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS
For more information about this report visit https://www.researchandmarkets.com/r/ytgwdi
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
SOURCE Research and Markets
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.